Skip to content

Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04798274
Enrollment
106
Registered
2021-03-15
Start date
2021-06-15
Completion date
2027-06-30
Last updated
2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

GABA, Language, ASD, MEG, MRS

Brief summary

Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental syndrome. Researchers think brain development may be controlled by gamma-aminobutyric acid (GABA). They want to learn how abnormalities in the GABA system may contribute to ASD. Objective: To see if repetitive transcranial magnetic stimulation (rTMS) creates short-term changes in how different parts of the brain communicate. Eligibility: Right-handed people ages 11-17 with ASD, and healthy volunteers ages 18-25. Design: Participants will be screened with: Medical history Physical exam Medicine review Neurological exam Psychological tests and rating scales Forms and surveys. Participants will have a hearing test and ear exam. Participants will have magnetic resonance imaging (MRI) of the brain. They will lie on a table that moves in and out of the MRI scanner. They may look at a screen while in the scanner. A coil will be placed over their head. Participants will have magnetic resonance spectroscopy. It takes pictures of chemicals in the brain using the MRI scanner. Participants will have magnetoencephalography. They will sit in a chair. A helmet with magnetic field sensors will be placed on their head. Participants will have TMS. A wire coil will be held on their scalp. A brief electrical current will pass through the coil. Participants will have electromyography. Sticky pad electrodes will be placed on the skin during TMS. The electrical activity of their muscles will be measured. Participants will have rTMS. It uses short bursts of magnetic pulses to affect brain activity. ASD participants may have visits scheduled as often as 1 time a week or as far apart as 2 months based on the participants or study team's availability. Healthy volunteers will have 3 visits over 3-4 weeks....

Detailed description

Study Description: This will be a within-subject, controlled, proof-of-mechanism study. Objectives: The study aims to evaluate the relationship between local GABA concentration, structural and functional network connectivity and MEG measures of auditory and language processing in adolescents with ASD and the acute impact of a single session of continuous theta burst stimulation over left posterior superior temporal cortex (pSTC) on these measures. We hypothesize that GABA concentrations, DWI measures of tissue microstructure and fcMRI obtained BOLD correlations within the language network will significantly contribute to the prediction model for MEG indices of auditory and language processing. Participation in the study involves about seven study visits. Some of the visits may be split up to shorten the length of session and limit fatigue. Visits may be scheduled as frequent as about once a week or as far apart as two months per the patient or study team's availability. All visits must be completed within six months of the date of enrollment. Primary Objective: The overall goal of the current study is to 1) Characterize the relationship between an individual's baseline local cortical GABA concentration, DWI measures of auditory and language network tissue microstructure, and fcMRI indices of local and long-range network functional connectivity (predictor variables) and MEG indices of auditory and language processing (dependent variables). Secondary Objectives: 2) Evaluate the impact of a single session of cTBS over the left pSTC on these MRS and MEG indices in adolescents (age 11-17) with ASD. Exploratory Objective: 3) Characterize the relationship between the neuroimaging and electrophysiological indices obtained in this study and baseline behavioral symptom presentation. Endpoints: Primary Endpoints: 1. MEG: Evoked fields and Spectral Power 2. MRS: GABA+/Cr concentrations in the left pSTC 3. DWI: Diffusion derived parameters in the auditory radiations and arcuate fasciculus. 4. fcMRI: BOLD correlations across pre-defined ROIs. Secondary Endpoints: a. MEG: Inter-trial gamma-band coherence (ITC) and resting state alpha to gamma phase-amplitude coupling. Exploratory Endpoints: a. SRS-2, CELF-5, EVT-3, PPVT-5, ADOS-2 (if available), ADI-R, VABS-III, WASI-II, CBCL, EDI.

Interventions

Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.

Sponsors

National Institute of Mental Health (NIMH)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
11 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* INCLUSION CRITERIA: Pilot Phase Inclusion criteria * Ability to provide informed consent * Age: 18-25 years * Must meet the definition of "Healthy Control" having completed the screening assessment under protocol 01-M-0254, "The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers" or under protocol 17-M-0181, "Recruitment and Characterization of Research Volunteers for NIMH Intramural Studies". Main Study Phase Inclusion criteria * Ability to provide informed assent and parent consent (Parents of children enrolling on the study do not need to be able to speak English. A consent form is available in English or Spanish for parents of children who enroll.) * Age: 11-17 years * Community Diagnosis of ASD based on DSM-IV or DSM-5 criteria (reviewed by a member of the Neurodevelopmental and Behavioral Phenotyping Service) * Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II). WASI-II will be used as a measure of intellectual function. Children will be included when FSIQ \> 70. * Right-handed: to reduce heterogeneity. * Hearing: Normal hearing in order to complete the behavioural assessments.

Exclusion criteria

Participants will be screened to exclude individuals with co-occurring neurological or medical conditions that might confound the results, as well as to exclude subjects in whom MRI or rTMS might result in increased risk of side effects or complications. This accounts for the majority of the

Design outcomes

Primary

MeasureTime frameDescription
MRSimmediately pre and post rTMSGABA+/Cr concentrations in the left pSTC
MEGimmediately pre and post rTMSEvoked fields and Spectral Power
fcMRIimmediately pre and post rTMSBOLD correlations across pre-defined ROIs.
DTIimmediately pre and post rTMSDiffusion tensor derived parameters in the auditory radiations and arcuate fasciculus.

Secondary

MeasureTime frameDescription
Neuropsychological AssessmentsBaselineSRS-2, CELF-5, EVT, PPVT, ADOS-2, ADI-R, VABS-III, WASI-II.
MEGimmediately pre and post rTMSInter-trial gamma-band coherence (ITC) and resting state alpha to gamma phase-amplitude coupling.

Countries

United States

Contacts

CONTACTLindsay M Oberman, Ph.D.
lindsay.oberman@nih.gov(301) 435-7962
CONTACTDaniel S Pine, M.D.
daniel.pine@nih.gov(301) 594-1318
PRINCIPAL_INVESTIGATORDaniel S Pine, M.D.

National Institute of Mental Health (NIMH)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026